Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.41
Q's Cash to Debt is ranked lower than
75% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. Q: 0.41 )
Ranked among companies with meaningful Cash to Debt only.
Q' s Cash to Debt Range Over the Past 10 Years
Min: 0.19  Med: 0.38 Max: N/A
Current: 0.41
Equity to Asset -0.12
Q's Equity to Asset is ranked lower than
93% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.58 vs. Q: -0.12 )
Ranked among companies with meaningful Equity to Asset only.
Q' s Equity to Asset Range Over the Past 10 Years
Min: -0.55  Med: -0.21 Max: -0.1
Current: -0.12
-0.55
-0.1
Interest Coverage 6.79
Q's Interest Coverage is ranked lower than
79% of the 121 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 96.50 vs. Q: 6.79 )
Ranked among companies with meaningful Interest Coverage only.
Q' s Interest Coverage Range Over the Past 10 Years
Min: 2.79  Med: 3.46 Max: 6.79
Current: 6.79
2.79
6.79
F-Score: 7
Z-Score: 3.44
M-Score: -2.46
WACC vs ROIC
5.14%
49.45%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 11.26
Q's Operating margin (%) is ranked higher than
75% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.48 vs. Q: 11.26 )
Ranked among companies with meaningful Operating margin (%) only.
Q' s Operating margin (%) Range Over the Past 10 Years
Min: 7.98  Med: 9.57 Max: 11.27
Current: 11.26
7.98
11.27
Net-margin (%) 6.83
Q's Net-margin (%) is ranked higher than
70% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.52 vs. Q: 6.83 )
Ranked among companies with meaningful Net-margin (%) only.
Q' s Net-margin (%) Range Over the Past 10 Years
Min: 3.65  Med: 5.02 Max: 6.83
Current: 6.83
3.65
6.83
ROA (%) 10.63
Q's ROA (%) is ranked higher than
86% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. Q: 10.63 )
Ranked among companies with meaningful ROA (%) only.
Q' s ROA (%) Range Over the Past 10 Years
Min: 7.36  Med: 10.72 Max: 20.82
Current: 10.63
7.36
20.82
ROC (Joel Greenblatt) (%) 325.27
Q's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -11.24 vs. Q: 325.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
Q' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 211.6  Med: 309.22 Max: 338.42
Current: 325.27
211.6
338.42
Revenue Growth (3Y)(%) 3.40
Q's Revenue Growth (3Y)(%) is ranked lower than
55% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.20 vs. Q: 3.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
Q' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 3.4  Med: 4.3 Max: 6.2
Current: 3.4
3.4
6.2
EBITDA Growth (3Y)(%) 13.00
Q's EBITDA Growth (3Y)(%) is ranked higher than
70% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. Q: 13.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
Q' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 2.4  Med: 13 Max: 19.1
Current: 13
2.4
19.1
EPS Growth (3Y)(%) 26.80
Q's EPS Growth (3Y)(%) is ranked higher than
84% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. Q: 26.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
Q' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 9.2  Med: 9.9 Max: 26.8
Current: 26.8
9.2
26.8
» Q's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

Q Guru Trades in Q3 2015

Ken Fisher 48,277 sh (+526.97%)
Ron Baron 472,105 sh (-2.12%)
Vanguard Health Care Fund 5,294,008 sh (-6.07%)
Jim Simons 249,300 sh (-7.29%)
Joel Greenblatt 329,978 sh (-14.04%)
Paul Tudor Jones 12,300 sh (-22.53%)
» More
Q4 2015

Q Guru Trades in Q4 2015

John Hussman 50,000 sh (New)
Paul Tudor Jones 28,686 sh (+133.22%)
Ken Fisher 54,173 sh (+12.21%)
Ron Baron 507,583 sh (+7.51%)
Vanguard Health Care Fund 4,774,398 sh (-9.82%)
Jim Simons 175,100 sh (-29.76%)
Joel Greenblatt 76,919 sh (-76.69%)
» More
Q1 2016

Q Guru Trades in Q1 2016

Columbia Wanger 1,375,000 sh (New)
Jim Simons 660,100 sh (+276.98%)
Joel Greenblatt 224,517 sh (+191.89%)
Ron Baron 516,806 sh (+1.82%)
John Hussman Sold Out
Ken Fisher 54,064 sh (-0.20%)
Paul Tudor Jones 23,076 sh (-19.56%)
Vanguard Health Care Fund 1,932,338 sh (-59.53%)
» More
Q2 2016

Q Guru Trades in Q2 2016

John Paulson 164,200 sh (New)
Larry Robbins 1,919,555 sh (New)
Ken Fisher 88,164 sh (+63.07%)
Paul Tudor Jones 37,446 sh (+62.27%)
Joel Greenblatt 350,600 sh (+56.16%)
Vanguard Health Care Fund 2,929,638 sh (+51.61%)
Jim Simons 528,700 sh (-19.91%)
Columbia Wanger 1,010,406 sh (-26.52%)
Ron Baron 371,210 sh (-28.17%)
» More
» Details

Insider Trades

Latest Guru Trades with Q

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:IDXX, NAS:DXCM, OTCPK:ERFSF, NYSE:DGX, NAS:QGEN, NYSE:PKI, OTCPK:BMXMF, OTCPK:SSMXY, NYSE:BIO, NAS:ICLR, NYSE:LH, NYSE:CRL, NAS:VWR, NAS:PRXL, NAS:BRKR, OTCPK:DSRLF, NYSE:ALR, NAS:PRAH, OTCPK:SWTUY, OTCPK:CZMWY » details
Traded in other countries:QTS.Germany,
Quintiles Transnational Holdings Inc provides biopharmaceutical development services and commercial outsourcing services. Its two operating segments are Product Development segment and Integrated Healthcare Services segment.

Quintiles Transnational Holdings Inc was founded in February 1982. The Company completed its initial public offering on May 9, 2013. The Company is engaged in providing biopharmaceutical development services and commercial outsourcing services. The Company's services offerings, helps biopharmaceutical customers, as well as customers in the healthcare industry, to make decisions regarding drug development, commercialization and drug therapy choices. The Company offers services through two segments Product Development; and Integrated Healthcare Services. The Product Development segment provides services and expertise that allow biopharmaceutical companies to outsource the clinical development process from first-in-man trials to post-launch monitoring. Its service offering provides the support and functional expertise necessary at each stage of development, as well as the systems and analytical capabilities to help customers improve product development efficiency and effectiveness. It is comprised of clinical solutions and services and consulting. Clinical solutions and services provide services to develop biopharmaceutical products including project management and clinical monitoring functions for conducting multi-site trials; clinical trial support services that improve clinical trial decision-making, such as laboratories, data management, bio-statistical, safety and pharmacovigilance, early clinical development trials and strategic planning and design services. Consulting provides management consulting services based on life science expertise and analytics, as well as regulatory and compliance consulting services. The Integrated Healthcare Services segment provides the healthcare industry with both geographic presence and commercial capabilities. Its customized commercialization services are designed to accelerate the commercial success of biopharmaceutical and other health-related products. It provides services including commercial services, such as providing contract pharmaceutical sales forces in geographic markets, as well as a growing number of healthcare business services for the broader healthcare sector. Its service offerings include commercial services and other healthcare services. The Company faces competition from traditional CROs, the in-house R&D departments of biopharmaceutical companies, universities and teaching hospitals. Its competitors include; Covance, Inc., Pharmaceutical Product Development, Inc., PAREXEL International Corporation, ICON plc, inVentiv Health, Inc., or inVentiv, INC Research, PRA International, United Drug plc, inVentiv, EPS Corporation and CMIC HOLDINGS Co., Ltd in Japan. In the United States, pharmaceutical, biological and medical device products are subject to extensive regulation by the FDA. Its integrated healthcare services are subject to numerous federal and state laws pertaining to promotional activities involving pharmaceutical products and medical devices, such as the FDA's regulati

Ratios

vs
industry
vs
history
P/E(ttm) 23.31
Q's P/E(ttm) is ranked higher than
66% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.71 vs. Q: 23.31 )
Ranked among companies with meaningful P/E(ttm) only.
Q' s P/E(ttm) Range Over the Past 10 Years
Min: 18.67  Med: 23.84 Max: 31.48
Current: 23.31
18.67
31.48
Forward P/E 19.88
Q's Forward P/E is ranked higher than
57% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.01 vs. Q: 19.88 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 23.31
Q's PE(NRI) is ranked higher than
66% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.41 vs. Q: 23.31 )
Ranked among companies with meaningful PE(NRI) only.
Q' s PE(NRI) Range Over the Past 10 Years
Min: 18.67  Med: 23.84 Max: 31.48
Current: 23.31
18.67
31.48
Price/Owner Earnings (ttm) 18.86
Q's Price/Owner Earnings (ttm) is ranked higher than
71% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.37 vs. Q: 18.86 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
Q' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 15.42  Med: 17.45 Max: 18.94
Current: 18.86
15.42
18.94
P/S 1.60
Q's P/S is ranked higher than
73% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.25 vs. Q: 1.60 )
Ranked among companies with meaningful P/S only.
Q' s P/S Range Over the Past 10 Years
Min: 1.02  Med: 1.39 Max: 1.77
Current: 1.6
1.02
1.77
PFCF 17.94
Q's PFCF is ranked higher than
68% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.29 vs. Q: 17.94 )
Ranked among companies with meaningful PFCF only.
Q' s PFCF Range Over the Past 10 Years
Min: 14.22  Med: 21.63 Max: 35.19
Current: 17.94
14.22
35.19
POCF 15.02
Q's POCF is ranked higher than
63% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.28 vs. Q: 15.02 )
Ranked among companies with meaningful POCF only.
Q' s POCF Range Over the Past 10 Years
Min: 12.28  Med: 17.14 Max: 26.51
Current: 15.02
12.28
26.51
EV-to-EBIT 15.90
Q's EV-to-EBIT is ranked higher than
65% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.76 vs. Q: 15.90 )
Ranked among companies with meaningful EV-to-EBIT only.
Q' s EV-to-EBIT Range Over the Past 10 Years
Min: 13.7  Med: 16.3 Max: 18.9
Current: 15.9
13.7
18.9
EV-to-EBITDA 13.35
Q's EV-to-EBITDA is ranked higher than
63% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 15.60 vs. Q: 13.35 )
Ranked among companies with meaningful EV-to-EBITDA only.
Q' s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.5  Med: 13.5 Max: 15.7
Current: 13.35
11.5
15.7
PEG 2.05
Q's PEG is ranked higher than
61% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.76 vs. Q: 2.05 )
Ranked among companies with meaningful PEG only.
Q' s PEG Range Over the Past 10 Years
Min: 0  Med: 0 Max: 10013.4
Current: 2.05
0
10013.4
Current Ratio 1.52
Q's Current Ratio is ranked lower than
78% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.42 vs. Q: 1.52 )
Ranked among companies with meaningful Current Ratio only.
Q' s Current Ratio Range Over the Past 10 Years
Min: 1.15  Med: 1.42 Max: 1.65
Current: 1.52
1.15
1.65
Quick Ratio 1.52
Q's Quick Ratio is ranked lower than
69% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. Q: 1.52 )
Ranked among companies with meaningful Quick Ratio only.
Q' s Quick Ratio Range Over the Past 10 Years
Min: 1.15  Med: 1.42 Max: 1.65
Current: 1.52
1.15
1.65
Days Sales Outstanding 38.06
Q's Days Sales Outstanding is ranked higher than
82% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 66.20 vs. Q: 38.06 )
Ranked among companies with meaningful Days Sales Outstanding only.
Q' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.13  Med: 29.27 Max: 38.06
Current: 38.06
25.13
38.06

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.40
Q's 3-Year Average Share Buyback Ratio is ranked higher than
73% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.70 vs. Q: -0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
Q' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.2  Med: -1.7 Max: -0.4
Current: -0.4
-3.2
-0.4

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.15
Q's Price/Median PS Value is ranked lower than
61% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.99 vs. Q: 1.15 )
Ranked among companies with meaningful Price/Median PS Value only.
Q' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.74  Med: 0.97 Max: 1.2
Current: 1.15
0.74
1.2
Earnings Yield (Greenblatt) (%) 6.28
Q's Earnings Yield (Greenblatt) (%) is ranked higher than
84% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.20 vs. Q: 6.28 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
Q' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 5.3  Med: 6.1 Max: 7.3
Current: 6.28
5.3
7.3

More Statistics

Revenue (TTM) (Mil) $5,989
EPS (TTM) $ 3.32
Beta0.55
Short Percentage of Float8.92%
52-Week Range $55.01 - 78.86
Shares Outstanding (Mil)118.48

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 4,634 4,903 5,133
EPS ($) 3.79 4.21 4.65
EPS w/o NRI ($) 3.79 4.21 4.65
EPS Growth Rate
(3Y to 5Y Estimate)
44.45%
Dividends Per Share ($)
» More Articles for NYSE:Q

Headlines

Articles On GuruFocus.com
The Big 3: Larry Robbins' Top 2nd-Quarter Buys Aug 16 2016 
Weekly 3-Year Low Highlight: TDC, Q, GRAM, XCO Dec 09 2013 
Vanguard Health Care Fund Gains 27%, Buys 4 New Stocks Jul 31 2013 
AT&T Inc. (T) Dividend Stock Analysis Jan 27 2011 
Stocks Jim Simons Keeps on Buying: CL, Q, LMT, NVO, HRB Jan 25 2011 
CenturyLink, Inc. – A Qwest for Growth Nov 22 2010 
Which S&P 500 Company Has the Shakiest Dividend: AT&T, Pepco, Qwest, CenturyTel, Diamond Offshore May 17 2010 

More From Other Websites
Quintiles, IMS Health tap execs for leadership roles post-deal Aug 29 2016
John Paulson Bought These 5 Stocks -- but the Charts Say Sell Aug 29 2016
IMS Health and Quintiles Announce Key Officers for Merged Company Aug 29 2016
IMS Health and Quintiles Announce Key Officers for Merged Company Aug 29 2016
QUINTILES TRANSNATIONAL HOLDINGS INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Aug 29 2016
IMS Health and Quintiles Announce Key Officers for Merged Company Aug 29 2016
Quintiles Poised To Benefit From Pharmaceutical R&D Outsourcing Aug 18 2016
Quintiles gets boost in 2Q, how other Triangle CROs fared Aug 17 2016
The Big 3: Larry Robbins' Top 2nd-Quarter Buys Aug 16 2016
EU clears merger between healthcare data firms IMS and Quintiles Aug 16 2016
ETF’s with exposure to Quintiles Transnational Holdings, Inc. : August 8, 2016 Aug 08 2016
[$$] 3i Makes 3.3-Times Return on Contract Research Organization Quintiles Aug 04 2016
[$$] Potential Biogen Buyout May Not Roil Quintiles Aug 03 2016
Quintiles Transnational Holdings, Inc. :Q-US: Earnings Analysis: Q2, 2016 By the Numbers : August 3,... Aug 03 2016
QUINTILES TRANSNATIONAL HOLDINGS INC. Financials Aug 02 2016
Quintiles and DaVita Clinical Research Announce Strategic Alliance Aug 02 2016
Quintiles and DaVita Clinical Research Announce Strategic Alliance Aug 02 2016
Why Illumina, Goodyear, Wyndham, and 2 Other Stocks Have Traders Buzzing Jul 27 2016
Traders Are Watching Closely Illumina, Edwards Lifesciences & Three Other Stocks Today Jul 27 2016
Edited Transcript of Q earnings conference call or presentation 27-Jul-16 12:00pm GMT Jul 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)